Details checkedClinical trial listing onlyCheckedregistry

Wayne State etanercept blast/noise-induced tinnitus study

Also known as: Etanercept, Enbrel, TNF-alpha treatment of blast-induced tinnitus, PR172190, NCT04066348

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Biologic

Stage

Phase 2

Status

Active

Target Gene

—

Route / Mode

Subcutaneous injection

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, tinnitus, noise-induced, blast-exposure, traumatic-brain-injury

Trial IDs

Mechanism

Subcutaneous etanercept, a TNF-alpha blocker, evaluated against placebo for tinnitus distress and hearing outcomes in adults with blast/noise/TBI-associated tinnitus.

Indications

Tinnitus Hearing Loss Noise-Induced Hearing Loss

Notes

Corrected from an institution primary sponsor row into a verified Wayne State-led Phase 2 biologic tinnitus study. No company sponsor is listed; Michigan Ear Institute is a collaborator of unknown class, not the primary company.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT04066348, PR172190

Open

Key Events

2019-08-26

Etanercept blast/noise tinnitus trial first posted

2026-02-23

ClinicalTrials.gov update lists the etanercept study as recruiting

Clinical Trials (1)